# A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

> **NCT07010263** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 560 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** AK112
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07010263
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-13
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010263, "A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07010263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*